The pharmacology of bimatoprost (Lumigan™)

Survey of Ophthalmology

Volumn 45, Issue SUPPL. 4, 2001, Pages

  Woodward, D F ^a   Krauss, A H P ^a   Chen, J ^a   Lai, R K ^a   Spada, C S ^a   Burk, R M ^a   Andrews, S W ^a   Shi, L ^a   Liang, Y ^a   Kedzie, K M ^a   Chen, R ^a   Gil, D W ^a   Kharlamb, A ^a   Archeampong, A ^a   Ling, J ^a   Madhu, C ^a   Ni, J ^a   Rix, P ^a   Usansky, J ^a   Usansky, H ^a   Weber, A ^a   Welty, D ^a   Yang, W ^a   Tang Liu, D D S ^a   Garst, M E ^a   Brar, B ^a   Wheeler, L A ^a   Kaplan, L J ^a   more..

^a ALLERGAN INC   (United States)

Author keywords

Anandamide; Bimatoprost; Cyclooxygenase; Glaucoma; Ocular hypertension; Prostamides

Indexed keywords

ADENOSINE RECEPTOR; ADRENERGIC RECEPTOR; AMIDE; ANANDAMIDE; ANTIGLAUCOMA AGENT; BIMATOPROST; CANNABINOID RECEPTOR; DOPAMINE RECEPTOR; FATTY ACID; ION CHANNEL; LONG ACTING DRUG; MUSCARINIC RECEPTOR; PROSTAMIDE DERIVATIVE; PROSTANOID RECEPTOR; RECEPTOR; SEROTONIN RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BIOSYNTHESIS; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; EYE; INTRAOCULAR PRESSURE; INTRAOCULAR PRESSURE ABNORMALITY; PERMEABILITY; PRIORITY JOURNAL; SCLERA; SPHINCTER PUPILLAE MUSCLE;

AMIDES; ANIMALS; ANTIHYPERTENSIVE AGENTS; GLAUCOMA; INTRAOCULAR PRESSURE; IRIS; LIPIDS; MUSCLE, SMOOTH; OCULAR HYPERTENSION;

EID: 0034766578     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6257(01)00224-7     Document Type: Article

References (18)

1. Further studies on the influence of the IOP on aqueous humor dynamics in cynomolgus monkeys
2. Comparison of once and twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: A 3-month clinical trial
3. Effects of bimatoprost, a new ocular hypotensive agent, on aqueous humor dynamics
4. Control of pain initiated by endogenous cannabinoids
5. Chemical characterization of a family of brain lipids that induce sleep
6. Isolation and structure of a brain constituent that binds to the cannabinoid receptor
7. "Endocannabinoids" and other fatty acid derivatives with cannabimimetic properties: Biochemistry and possible physiological relevance
8. Efficacy and safety of the ocular hypotensive lipid AGN 192024 in patients with elavated IOP: A 30-day comparison with latanoprost
9. Tissues grafted into the cheek pouch of the hamster
10. Evidence for a novel receptor in the cat iris that recognizes prostaglandin F2α (PGF2α) analogs with a neutral substituent at position 1
11. Comparison of the ocular hypotensive lipid AGN 192024 with timolol: Dosing, efficacy and safety evaluation of a novel compound for glaucoma management
12. Expression of cyclooxygenase-2 in normal and glaucomatous eyes
13. GLCIA-locus: Mutation screening in MYOC/TIGR and COX-2 of German POAG patients
14. Structure-activity relationships and receptor profiles of some ocular hypotensive prostanoids
15. Effect of PhXA41, a new prostaglandin PGF2α analog, on aqueous humor dynamics in human eyes
16. Replacement of the carboxylic acid group of prostaglandin F2α with a hydroxyl or methoxy substituent provides biologically unique compounds
17. Prostaglandin F2α (PGF2α) 1-ethanolamide: A pharmacologically unique local hormone biosynthesized from anandamide
18. Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2